RTI Surgical® Wins 2019 MedTech Breakthrough Award for TETRAfuse® 3D Technology

Posted by on Jun 10, 2019 in Newsroom | 0 comments

ALACHUA, FL. and DEERFIELD, IL. – RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced MedTech Breakthrough has selected TETRAfuse® 3D Technology as the “Best New Technology Solution – Orthopedics” in their 2019 Awards Program. MedTech Breakthrough is an independent organization recognizing the top companies and solutions in the global health and medical technology market. This year’s program attracted more than 3,500 nominations from over 15 different countries. TETRAfuse 3D Technology is featured in RTI’s growing family of...

Read More

TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States

Posted by on Jun 10, 2019 in Newsroom | 0 comments

BOCA RATON, FL. – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners. Theramex will have exclusive commercialization rights for BIJUVA and IMVEXXY outside the U.S., excluding Canada and...

Read More

NCBiotech-funded microscope sheds light on brain circuitry of binge eating

Posted by on Jun 7, 2019 in Newsroom | 0 comments

CHAPEL HILL, N.C. – Ever wondered why you can’t eat just one? Be it chips or chocolate – or drugs or alcohol – neuroscientists have spent decades trying to uncover the reasons why people binge. With support from a $200,000 instrumentation grant from the North Carolina Biotechnology Center in 2016, researchers at the University of North Carolina at Chapel Hill have discovered a brain circuit about hedonic versus homeostatic feeding in mice. That is, what drives them to binge eat calorie-rich food that tastes good (hedonic) versus what drives them to eat only in response to...

Read More

India-Based KriGen Pharmaceuticals Chooses Lillington, North Carolina, for U.S. Operations

Posted by on Jun 7, 2019 in Newsroom | 0 comments

LILLINGTON, N.C. – KriGen Pharmaceuticals, an India-based pharmaceutical company, will invest $7 million to locate its first U.S. production plant in Lillington, North Carolina. The project is expected to create 100 jobs in Harnett County. A privately held Indian company, KriGen Pharmaceuticals will manufacture medical IV bags and liquid injectables in its new 55,000 square-foot state-of-the-art facility. The company aims to improve quality of life for patients with affordable pharmaceutical solutions and services through innovation and technology. KriGen researches and develops...

Read More

Medical Device Company MLM Biologics Graduates from UF Innovate | Sid Martin Biotech Program

Posted by on May 28, 2019 in Newsroom | 0 comments

ALACHUA, FL. – UF Innovate | Sid Martin Biotech, the leading biotechnology incubator at the University of Florida, is pleased to announce that resident company MLM Biologics, Inc. has graduated from its program. MLM Biologics is a medical device company that provides evidence-based solutions in the advance wound care and musculoskeletal clinical spaces. The company designs, develops, manufactures and commercializes clinical products that are aimed to offer the best medical-economic alternatives in those markets. The company is currently commercializing its flagship product, the...

Read More

ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’

Posted by on May 23, 2019 in Newsroom | 0 comments

BOCA RATON, FL. and RAMSEY, N.J. – ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon...

Read More